Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, alipogene tiparvovec (Glybera®) cannot be endorsed for use within NHS Wales for the treatment of adult patients diagnosed with familial lipoprotein lipase deficiency and suffering from severe or multiple pancreatitis attacks despite dietary fat restrictions. |
||
|
||
Medicine details |
||
| Medicine name | alipogene tiparvovec (Glybera®) | |
| Formulation | 3 × 10¹² genome copies/ml solution for injection | |
| Reference number | 645 | |
| Indication | Treatment of adult patients diagnosed with familial lipoprotein lipase deficiency and suffering from severe or multiple pancreatitis attacks despite dietary fat restrictions. |
|
| Company | UniQure Biopharma BV | |
| BNF chapter | Nutrition & blood | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 18/03/2013 | |